Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06728969 · ClinicalTrials.gov registry record · NA
A Comparative Study to Evaluate a Novel Algorithm As a Diagnostic Aid for ADHD in Youth Ages 6-17.
A NA study of ADHD, sponsored by MindTension.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06728969: Recruiting NA study of ADHD, sponsored by MindTension.
NCT06728969 is a NA study of ADHD that is actively recruiting participants, run by MindTension. The registered enrollment target is 120 participants, below the 189-participant average among 75 other ADHD trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06728969, a NA study of ADHD, is actively recruiting participants, sponsored by MindTension.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to demonstrate the accuracy of the MT1 algorithm using the MindTension biometric sensor device as a diagnostic aid for healthcare providers in diagnosing ADHD in youth ages ≥ 6 to ≤17 years.
Primary Outcome
The outcome measure will be calculated by using the following formula: Over All Agreement = (True Positive + True Negative) / (True Positive + True Negative + False Positive + False Negative) X 100.
Conditions Studied
Interventions
- DEVICE MT1 Auditory startle response patterns analysis algorithm
- DEVICE T.O.V.A. Continuous Performance Test
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-06-02 |
| Est. Completion | 2026-06 |
| Phase | NA |
What NCT06728969 shows while recruiting
NCT06728969 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 189-participant average among 75 other ADHD trials with a reported enrollment target (37% lower).
The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 2 interventions - of which MT1 Auditory startle response patterns analysis algorithm is the first listed.
NCT06728969 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06728969 about?
NCT06728969 is a clinical study titled "A Comparative Study to Evaluate a Novel Algorithm As a Diagnostic Aid for ADHD in Youth Ages 6-17.". This study aims to demonstrate the accuracy of the MT1 algorithm using the MindTension biometric sensor device as a diagnostic aid for healthcare providers in diagnosing ADHD in youth ages ≥ 6 to ≤17 years.
What is the current status of trial NCT06728969?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2024-06-02. Estimated completion is 2026-06.
What conditions does trial NCT06728969 study?
This clinical trial studies the following conditions: ADHD.
What interventions are being tested in trial NCT06728969?
The interventions under investigation include: MT1 Auditory startle response patterns analysis algorithm (DEVICE), T.O.V.A. Continuous Performance Test (DEVICE).
Who is sponsoring clinical trial NCT06728969?
This trial is sponsored by MindTension, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06728969 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06728969's enrollment target sits among peer trials
120 28th of 75 higher than 47 of 75 other ADHD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ADHD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)
RECRUITING · NA
-
Target ADHD Executive Working Memory Replication Study
RECRUITING · NA
-
Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)
RECRUITING · NA
-
Fidgeting and Attentional and Emotional Regulation in ADHD
RECRUITING · NA
-
Moms Managing Attention-Deficit/Hyperactivity Disorder (ADHD) Study
RECRUITING · NA
-
A Pilot Study of a Remote ADHD Monitoring Program
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI